121 related articles for article (PubMed ID: 34589964)
1. Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in
Haratake N; Misumi T; Yamanaka T; Seto T
JTO Clin Res Rep; 2020 Nov; 1(4):100085. PubMed ID: 34589964
[TBL] [Abstract][Full Text] [Related]
2. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
[TBL] [Abstract][Full Text] [Related]
3. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance.
Ma J; Tan SH; Yin DXC; Tran NTA; Tan GS; Lai GGY; Ang MK; Kanesvaran R; Jain A; Rajasekaran T; Tan EH; Lim TKH; Tan DS; Lim DW; Ng QS; Tan WL
Transl Lung Cancer Res; 2023 Apr; 12(4):742-753. PubMed ID: 37197627
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of patients taking first-generation EGFR-TKIs may predict the benefits afforded by osimertinib in EGFR T790M-mutant NSCLC patients.
Meng H; Huang L; Wang J; Zhou Y; Wang M; Yang Z; Hong X
Int J Clin Pract; 2021 Dec; 75(12):e14877. PubMed ID: 34525256
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors.
Hsu PC; Huang CY; Lin YC; Lee SH; Chiu LC; Wu CE; Kuo SC; Ju JS; Huang AC; Ko HW; Wang CC; Yang CT
Front Oncol; 2023; 13():1249106. PubMed ID: 37854677
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression.
Inomata M; Minatoyama S; Takata N; Hayashi K; Hirai T; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
Mol Clin Oncol; 2024 Jun; 20(6):43. PubMed ID: 38756869
[TBL] [Abstract][Full Text] [Related]
8. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
Peng D; Shan D; Dai C; Li J; Wang Z; Huang Z; Peng R; Zhao P; Ma X
Cancer Manag Res; 2021; 13():2033-2039. PubMed ID: 33679141
[TBL] [Abstract][Full Text] [Related]
10. Osimertinib in NSCLC: Real-World Data From New Zealand.
So YJ; Fraser A; Rivalland G; McKeage M; Sullivan R; Cameron L
JTO Clin Res Rep; 2020 Jun; 1(2):100022. PubMed ID: 34589929
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
Yi XF; Song J; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Ma JT; Han CB
Front Oncol; 2022; 12():863666. PubMed ID: 35785185
[TBL] [Abstract][Full Text] [Related]
12. Ideal sequencing in Stage IV epidermal growth factor receptor mutant Non-Small-Cell Lung Cancer.
Walia M; Singhal MK; Kamle MS
Indian J Cancer; 2022 Mar; 59(Supplement):S80-S89. PubMed ID: 35343193
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
Saad N; Poudel A; Basnet A; Gajra A
Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
[TBL] [Abstract][Full Text] [Related]
14. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance to osimertinib.
Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
[TBL] [Abstract][Full Text] [Related]
16. Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment.
Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Araya T; Hiraoka N; Ishizuka T; Takeda T; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517152
[TBL] [Abstract][Full Text] [Related]
17. Treatment pattern and outcomes in
Panda GS; Noronha V; Shah D; John G; Chougule A; Patil V; Kumar R; Menon N; Singh A; Chandrani P; Mahajan A; Prabhash K
Ecancermedicalscience; 2022; 16():1385. PubMed ID: 35919239
[TBL] [Abstract][Full Text] [Related]
18. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
[TBL] [Abstract][Full Text] [Related]
19. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
20. Machine Learning-Based CT Radiomics Analysis for Prognostic Prediction in Metastatic Non-Small Cell Lung Cancer Patients With
Tang X; Li Y; Yan WF; Qian WL; Pang T; Gong YL; Yang ZG
Front Oncol; 2021; 11():719919. PubMed ID: 34660285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
